From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .
EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), with an IC50 of 1 nM .
R9H6 is a peptide containing nine arginine peptides and six histidine peptides. The LP(R9H6)m nanocomplex containing R9H6 exhibits high efficiency in mRNA delivery. R9H6 can be used in the research of anaplastic thyroid cancer .
ASP3026 (Standard) is the analytical standard of ASP3026. This product is intended for research and analytical applications. ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .
ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC50 values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK WT, ALK L1196M and ALK G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC50 values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma .
Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor. Ficonalkib, can be used as an antineoplastic agent .
ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively .
Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
ALK protein ligand-1 (Compound A1), a ligand for the anaplastic lymphoma kinase (ALK) protein, is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) that exhibits inhibitory effects on ALK. ALK protein ligand-1 can be used in the synthesis of AP-1 (HY-169481) .
dALK-3 is an anaplastic lymphoma kinase (ALK) degrader. dALK-3 can effectively induce EML4-ALK degradation with a DC50 of 0.182 μM. dALK-3 has good anti-proliferation activity against H3122 cells and can be used in the study of cancer .
CEP-28122 mesylate hydrochloride is a diaminopyrimidine derivative.CEP-28122 mesylate hydrochloride is a potent, selective, and orally bioavailable ALK inhibitor with an IC50 of 1.9 nM. CEP-28122 mesylate hydrochloride has antitumor and good pharmacokinetic activity .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK has multiple mutants. ALK R1275Q is commonly found in neuroblastoma (NB). ALK R1275Q Recombinant Human Active Protein Kinase is a recombinant ALK R1275Q protein that can be used to study ALK R1275Q-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK L1196M Recombinant Human Active Protein Kinase is a recombinant ALK L1196M protein that can be used to study ALK L1196M-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK has multiple mutants. ALK-F1174L is commonly found in neuroblastoma (NB). ALK-F1174L Recombinant Human Active Protein Kinase is a recombinant ALK-F1174L protein that can be used to study ALK-F1174L-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK F1174S Recombinant Human Active Protein Kinase is a recombinant ALK F1174S protein that can be used to study ALK F1174S-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK C1156Y Recombinant Human Active Protein Kinase is a recombinant ALK C1156Y protein that can be used to study ALK C1156Y-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK G1202R Recombinant Human Active Protein Kinase is a recombinant ALK G1202R protein that can be used to study ALK G1202R-related functions .
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
ALK/EGFR-IN-3 is a dual inhibitor of ALK and EGFR. ALK/EGFR-IN-3 inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC50s of 0.1360, 0.0332, and 0.0339 μM, respectively .
ALK/EGFR-IN-2 is a potent dual inhibitor of ALK and EGFR. ALK/EGFR-IN-2 induces apoptosis and G0/G1 cell cycle arrest in cancer cells. ALK/EGFR-IN-2 significantly inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC50s of 0.0034, 0.0065, and 0.0018 μM, respectively .
Bayer-18 is an inhibitor for TYK2. Bayer-18 inhibits the viability of ALCL cell K299, SR786, Mac1 and Mac2a with IC50 of 2-3 µM, and induces apoptosis in K299 and SR786 .
Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .
Ganglioside GD1b Disodium Salt (Bovine Brain) (Disialoganglioside GD1b; Ganglioside C1) is an acidic glycosphingolipid containing two sialic acid residues linked to an internal galactose unit. Ganglioside GD1b Disodium Salt tightly packs with cholesterol to form lipid microdomains that modulate intracellular and intercellular signaling events. Concentrations of Ganglioside GD1b Disodium Salt (Bovine Brain) in the human brain increase with age and are positively correlated with pilocytic astrocytoma tumor grade. Ganglioside GD1b Disodium Salt has been detected in various other gliomas, including primitive neuroectodermal tumors, glioblastomas, and anaplastic astrocytomas.
Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity .
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune system's ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs) .
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 2,523 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
R9H6 is a peptide containing nine arginine peptides and six histidine peptides. The LP(R9H6)m nanocomplex containing R9H6 exhibits high efficiency in mRNA delivery. R9H6 can be used in the research of anaplastic thyroid cancer .
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune system's ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs) .
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
